Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial-Reference-Cited by-同舟云学术

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial

Published:2018-07-18 Issue:21 Volume:24 Page:5305-5312
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Toren Paul^ORCID,Hoffman Azik^ORCID,Ding Keyue,Joncas France-Hélène,Turcotte Véronique,Caron Patrick^ORCID,Pouliot Frédéric,Fradet Yves,Lévesque Éric,Guillemette Chantal,Klotz Laurence

Funder

Prostate Cancer Canada Movember Discovery Grant

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression;Journal of Clinical Investigation;2024-04-16

2. Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo;Nature Reviews Urology;2023-02-14

3. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer;Journal of Urology;2023-02

4. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level;Journal of Urology;2022-12

5. Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration‐resistant prostate cancer;The Prostate;2022-06-23